However, reduced hepatic UGT mRNA in inflamed tissue [32] and altered hepatic expression of some drug transporters, such as down-regulated MRP2 and up-regulated MDR1, MRP1, and MRP3 in livers of patients with HCV infection may be associated with differences in the pharmacokinetics of silymarin between patients with NAFLD and HCV chronic infection. Here, SLC35A2 is linked to metabolic dysfunction-associated steatotic liver disease.